We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Shares of Laval, Quebec-based ProMetic Life Sciences Inc. jumped more than 8.7 percent this morning after securing FDA’s Rare Pediatric Disease Designation for its Inter-Alpha-Inhibitor-Proteins treatment for necrotizing enterocolitis